Kolexia
Landman-Parker Judith Pédiatrie
Landman-Parker Judith
Pédiatrie
Hôpital Armand Trousseau
Paris, France
118 Activités
2 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Maladie de Hodgkin Leucémies Leucémie-lymphome lymphoblastique à précurseurs B et T Lymphome à grandes cellules anaplasiques Récidive tumorale locale Leucémie-lymphome lymphoblastique à précurseurs T Thrombopénie Lymphome malin non hodgkinien

Collaborateurs

Voir plus
Leblanc Thierry
Leblanc Thierry
Hôpital Robert-Debré, Paris, France
Leverger Guy
Leverger Guy
Hôpital Armand Trousseau, Paris, France
Aladjidi Nathalie
Aladjidi Nathalie
Hôpital Pellegrin, Bordeaux, France
Baruchel Andre
Baruchel Andre
Hôpital Robert-Debré, Paris, France

Industries

Voir plus
Jazz Pharmaceuticals
1 collaboration(s)
Dernière en 2019
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.
European journal of cancer (Oxford, England : 1990)   15 février 2024
Pulmonary lesions in early response assessment in pediatric Hodgkin lymphoma: prevalence and possible implications for initial staging.
Pediatric radiology   31 janvier 2024
(Cyclin F) as a Candidate Gene for Familial Hodgkin Lymphoma: Additional Evidence for the Importance of Mitotic Checkpoint Defects in Tumorigenesis.
HemaSphere   16 novembre 2023
Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE (SER) TO FRONT-LINE CHEMOTHERAPY (KEYNOTE-667)
Abstracts from the 55th Congress of the International Society of Paediatric Oncology (SIOP) October 11–14, 2023   02 novembre 2023
Digital pathology in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: correlation with treatment response.
Blood advances   23 octobre 2023
NIVO-ALCL: Phase II Trial of Nivolumab for Pediatric and Adult Relapsing/Refractory Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease Cohort 1 or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse Cohort 2
Essai Clinique (Gustave-Roussy)   09 octobre 2023
Combined germline and somatic human FADD mutations cause autoimmune lymphoproliferative syndrome.
The Journal of allergy and clinical immunology   02 octobre 2023
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib: A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Essai Clinique (BMS)   31 août 2023
DOCK11 deficiency in patients with X-linked actinopathy and autoimmunity.
Blood   13 juin 2023